Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell LymphomasMichele Merli, Luca Arcaini, Francesco Passamonti et al.|The Oncologist|2018Cited by 69
Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphomaVincenzo Occhipinti, Maria Grazia Rumi, Lucia Farina et al.|Digestive and Liver Disease|2018Cited by 18
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphomaAlessandro Loglio, Pietro Lampertico, Mauro Viganò et al.|Digestive and Liver Disease|2018Cited by 16
Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLLLydia Scarfò, Paolo Ghia, Silvia Heltai et al.|Blood|2022Cited by 10
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Monica Balzarotti, Valentina Tabanelli et al.|The Lancet Haematology|2025Cited by 6